

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--|---------------------|----------------------|-------------------------|------------------|
| 09/807,402 | 08/03/2001 | Peter Hofert | SCH 1808 | 9208 |
| 23599 7: | 590 03/28/2003 | | | |
| MILLEN, WHITE, ZELANO & BRANIGAN, P.C. 2200 CLARENDON BLVD. SUITE 1400 | | | EXAMINER | |
| | | | MAIER, LEIGH C | |
| ARLINGTON, | ARLINGTON, VA 22201 | | ART UNIT | PAPER NUMBER |
| | | | ARTONI | TATER NOMBER |
| | | | 1623 | A |
| | | | DATE MAILED: 03/28/2003 | ; '1 |

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/807,402

Applicant(s)

Hofert

Examiner

Leigh Maier

Art Unit **1623**



| | The MAILING DATE of this communication appears | n the cover sheet with the | correspondence address | | |
|--|--|--|---|--|--|
| | for Reply | | | | |
| THE N | ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION. | | | | |
| | ions of time may be available under the provisions of 37 CFR 1.136 (a). In a date of this communication. | o event, however, may a reply be tin | nery filed after SIX (6) MON I HS from the | | |
| - If NO p - Failure - Any re | period for reply specified above is less than thirty (30) days, a reply within the period for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b). | d will expire SIX (6) MONTHS from to application to become ABANDONED | the mailing date of this communication.) (35 U.S.C. § 133). | | |
| Status | | | | | |
| 1) 🗆 | Responsive to communication(s) filed on | | · | | |
| 2a) 🗌 | This action is FINAL . 2b) 💢 This action | on is non-final. | | | |
| 3) 🗆 | Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213. | | | | |
| Disposit | tion of Claims | | | | |
| 4) 💢 | Claim(s) <u>1-16</u> | | is/are pending in the application. | | |
| 4 | a) Of the above, claim(s) | | is/are withdrawn from consideration. | | |
| 5) 🗆 | Claim(s) | | is/are allowed. | | |
| 6) 🗆 | Claim(s) | | is/are rejected. | | |
| 7) 🗆 | Claim(s) | | is/are objected to. | | |
| 8) 💢 | Claims 1-16 | are subject to | restriction and/or election requirement. | | |
| Applica | tion Papers | | | | |
| 9) 🗌 | The specification is objected to by the Examiner. | | | | |
| 10) | The drawing(s) filed on is/are | a) 🗆 accepted or b) 🗀 o | bjected to by the Examiner. | | |
| | Applicant may not request that any objection to the d | awing(s) be held in abeyan | ce. See 37 CFR 1.85(a). | | |
| 11) | The proposed drawing correction filed on | is: a)□ appr | oved b) \square disapproved by the Examiner. | | |
| | If approved, corrected drawings are required in reply t | this Office action. | | | |
| 12) | The oath or declaration is objected to by the Exami | ner. | | | |
| Priority | under 35 U.S.C. §§ 119 and 120 | | | | |
| 13)□ | 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). | | | | |
| a) □ | ☐ All b)☐ Some* c)☐ None of: | | | | |
| | 1. \square Certified copies of the priority documents have | been received. | | | |
| : | 2. \square Certified copies of the priority documents have | been received in Applica | ition No | | |
| | 3. Copies of the certified copies of the priority do application from the International Burea | u (PCT Rule 17.2(a)). | - | | |
| *Se | ee the attached detailed Office action for a list of the | certified copies not rece | ved. | | |
| 14) | Acknowledgement is made of a claim for domestic | priority under 35 U.S.C. | i 119(e). | | |
| a) | | • • | | | |
| 15)∟ | Acknowledgement is made of a claim for domestic | priority under 35 U.S.C. § | §§ 120 and/or 121. | | |
| Attachme | | | | | |
| _ | tice of References Cited (PTO-892) | 4) Interview Summary (PTO-413 | | | |
| 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s). 6) Other: | | | | | |
| 2, 🗀 imi | Simulation Discussion Statement(s) (FTO 1443) Paper NO(S). | o, Li otilei. | | | |

Art Unit: 1623

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-7, 10, and 11 drawn to host-guest complex of a gestagen and a cyclodextrin and pharmaceutical compositions thereof.

Group II, claims 14-16, drawn to the preparation of a host-guest complex of a gestagen and a cyclodextrin.

Group III, claim 8, drawn to a method of treating menopausal symptoms comprising administration of a host-guest complex of a gestagen and a cyclodextrin.

Group IV, claims 9 and 13, drawn to a method of birth control comprising administration of a host-guest complex of a gestagen and a cyclodextrin.

Group V, claim 12, drawn to a method of treating premenstrual symptoms comprising administration of host-guest complex of a gestagen and a cyclodextrin.

The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special

Art Unit: 1623

technical features for the following reasons: All the groups require a host-guest complex of a gestagen and a cyclodextrin or a method of using or preparing said complex. However, Groups III-V are drawn to patentably distinct therapuetic methods. Therefore, the following sets of claim groupings have unity of invention, and Applicant is required to select one set of Groups from these for examination:

- A. Groups I-III (claims 1-8, 10, 11, and 14-16)
- B. Groups I, II, and IV (claims 1-7, 9-11, and 13-16)
- C. Groups I, II, and V (claims 1-7, 10-12, and 14-16)

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Examiner's hours, phone & fax numbers

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leigh Maier whose telephone number is (703) 308-4525. The examiner can normally be reached on Tuesday, Wednesday, or Friday 7:00 to 3:30 (ET).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson (703) 308-4624, may be contacted. The fax phone number for Group 1600, Art Unit 1623 is (703) 308-4556 or 305-3592.

Art Unit: 1623

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-1235.

Visit the U.S. PTO's site on the World Wide Web at http://www.uspto.gov. This site contains lots of valuable information including the latest PTO fees, downloadable forms, basic search capabilities and much more.

Leigh C. Maier Patent Examiner March 26, 2003